Evotec maps path to profitability

Germany's Evotec says that research alliances with top biopharma companies will push up sales by 20 percent for each of the next three years. And that would put the company on a path to become "sustainably" profitable in 2012. Evotec hasn't been profitable since it went public in 1999. Report

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.